{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"33.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"pt 1: progression free survival"},{"categories":[{"measurements":[{"groupId":"OG001","value":"1.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"pt 2: progression free survival"},{"categories":[{"measurements":[{"groupId":"OG002","value":"4.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"pt 3: progression free survival"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"pt 4: progression free survival"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"pt 5: progression free survival"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"Progressive Disease (PD)= ≥25% increase size of T1-Gd+ disease, or increased T2/FLAIR signal, or presence of new lesion, or worsening clinical status","groups":[{"description":"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle\n\nResearch Bloods\n\nEncorafenib: 450mg QD 28 day cycle\n\nBinimetinib: 45mg BID 28 day cycle\n\nResearch Bloods: Baseline; pre-cycle 3; Pre-cycle 7; off Treatment\n\nTumor Tissue: at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides","id":"OG000","title":"Treatment Cohort 1 AA & GBM"},{"description":"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle\n\nResearch Bloods\n\nEncorafenib: 450mg QD 28 day cycle\n\nBinimetinib: 45mg BID 28 day cycle\n\nResearch Bloods: Baseline; pre-cycle 3; Pre-cycle 7; off Treatment\n\nTumor Tissue: at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides","id":"OG001","title":"Treatment Cohort 2 Anaplastic PXAs"},{"description":"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle\n\nResearch Bloods\n\nEncorafenib: 450mg QD 28 day cycle\n\nBinimetinib: 45mg BID 28 day cycle\n\nResearch Bloods: Baseline; pre-cycle 3; Pre-cycle 7; off Treatment\n\nTumor Tissue: at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides","id":"OG002","title":"Treatment Cohort 3 Other Tumors"}],"paramType":"NUMBER","populationDescription":"Each row represents a specific patient. the number in that row equals the progression free survival for a specific patient, as there were only 5 patients\n\nDue to early termination, results are given per cohort per patient, as the data is meaningless otherwise due to small numbers","reportingStatus":"POSTED","timeFrame":"up to 3 years","title":"Progression Free Survival for 3 Treatment Cohorts","type":"SECONDARY","unitOfMeasure":"months"}